Cannabis and psychosis: the impact of polydrug use
Mark E. Shevlin, Eoin McElroy, Jamie Murphy, Philip Hyland, Frédérique Vallières, Ask Elklit, Mogens Nygaard Christoffersen
Drugs and Alcohol Today July 20, 2017 DOI: 10.1108/dat-03-2017-0014 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort (survey linked to administrative registry data) Peer reviewed |
|---|---|
| Sample size | 4,718 |
| Population | Young Danish people aged 24 |
| Topics | Cannabis |
| Citations | 8 |
| Key findings | Compared with no drug use, cannabis use alone did not increase the risk of psychosis, whereas the odds ratio for combined cannabis and other drug use was statistically significant. The authors suggest psychosis risk may be associated with the cumulative effect of polydrug use. |
Abstract
Purpose: While research has consistently identified an association between cannabis use and psychosis, few studies have examined this relationship in a polydrug context (i.e. combining cannabis with other illicit substances). The paper aims to discuss this issue. Design/methodology/approach The present study sought to examine the association between recreational drug use (cannabis only vs polydrug) and psychotic disorders. Analysis was conducted on a large, representative survey of young Danish people aged 24 (n=4,718). Participants completed self-report measures of lifetime drug use and this information was linked to the Danish psychiatric registry system.
Findings: Multivariate binary logistic regression analysis was used to examine the association between drug use (no drug use, cannabis only, cannabis and other drug) and ICD-10 psychotic disorders, while controlling for gender and parental history of psychosis. Compared with no drug use, the use of cannabis only did not increase the risk of psychosis while the odds ratio for cannabis and other drug were statistically significant. Research limitations/implications Psychosis risk may be associated with the cumulative effect of polydrug use. Practical implications Cannabis use may be a proxy for other drug use in research studies. Originality/value This study is innovative as it uses linked self-report and administrative data for a large sample. Administrative data were used to as an objective mental health status indicator.
Comparable studies
Other cross-sectional and survey studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Cannabis use before age 15 and subsequent executive functioning 104 chronic cannabis users (49 early-onset before age 15, 55 late-onset after age 15)... | 2011 | Observational cross-sectional study | n = 148 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
| Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey Online survey respondents | 2020 | Cross-sectional survey | |
| User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study Users of hallucinogenic drugs who completed a web-based questionnaire | 2010 | Cross-sectional survey | n = 600 |
| Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner Adults recruited from the MAPS website and newsletter, most reporting use of various... | 2012 | Cross-sectional survey | n = 337 |
Citations in the library
Cites 7
- Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol Archives of General Psychiatry April 1, 2009
- Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biological Psychiatry April 1, 2016
- Cannabis and Psychosis: a Critical Overview of the Relationship. Current Psychiatry Reports February 1, 2016
- Cannabis use and psychosis: re-visiting the role of childhood trauma. Psychological Medicine November 1, 2011
- An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropharmacology February 23, 2011
and 2 more in the library